Form 4: Director's Equity Changes at Dyadic International

Dyadic International Director Patrick K. Lucy reported significant equity transactions, including the settlement of restricted stock units and new grants of stock options and restricted stock units.

Summary

• Director Patrick K. Lucy acquired 21,552 shares of Dyadic International Inc. common stock on January 2, 2026, bringing total direct beneficial ownership to 72,311 shares.
• This acquisition resulted from the settlement of previously vested restricted stock units.
• Lucy was granted 67,500 stock options with an exercise price of $0.94, exercisable from January 2, 2027, and expiring on January 2, 2036.
• An additional 39,894 restricted stock units were granted, which will vest upon the first anniversary of the grant date, subject to continued service.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, including new grants and the settlement of vested units, which is generally positive for aligning management interests with shareholders. No negative events are reported.

Positives

• Director Patrick K. Lucy received an annual grant of 67,500 stock options, indicating continued incentive alignment with shareholder interests.
• An annual grant of 39,894 restricted stock units was issued, further aligning the director's long-term interests with the company's performance.
• The settlement of 21,552 restricted stock units into common stock increases the director's direct ownership of the company's equity.

Future Outlook

The newly granted restricted stock units are subject to vesting upon the first anniversary of the grant date, contingent on continued service as a board member, indicating a future commitment.

Industry Context

These transactions represent routine director compensation and equity incentive alignment, common practice across publicly traded companies to retain and motivate board members.

Comparison to Industry Standards

• The grants of stock options and restricted stock units are standard components of director compensation packages in the biotechnology and life sciences industry, similar to practices at companies like Novozymes or Codexis, which also utilize equity incentives to align director interests with long-term company performance.
• The vesting schedule for RSUs and the exercise period for options are typical for such grants.

Stakeholder Impact

• Shareholders: The grants align the director's interests with long-term shareholder value.
• Employees: No direct impact on general employees is indicated.

Next Steps

• The 39,894 restricted stock units granted on January 2, 2026, will vest upon the first anniversary of the grant date, subject to continued service.
• The 67,500 stock options granted on January 2, 2026, will become exercisable on January 2, 2027.

Key Dates

Recommendation

This Form 4 details routine equity compensation for a director, including grants of stock options and restricted stock units, and the settlement of previously vested units. These transactions are standard practice for aligning director incentives with company performance and do not provide new information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing does not present new material information to alter current positions.

Keywords

Dyadic International, DYAI, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Beneficial Ownership